Meet us at the 2024 ISPE Annual Meeting in Berlin!

The International Society for Pharmacoepidemiology (ISPE) will hold their 40^th Annual Meeting in Berlin, August 2024. The ISPE meeting, formerly known as the International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) is an important milestone in the pharmacoepidemiology calendar where academics, industry professionals and experts from across the world gather to share groundbreaking results, discuss latest progress and work through current challenges in the field. The theme of the 2024 meeting is “Celebrating 40 Years of Advancing Pharmacoepidemiology”.

Teamit Institute’s presence at ISPE Meetings

Teamit Institute has actively taken part in ISPE meetings over the last few years, with poster presentations and active involvement in discussions. Previous meetings have seen poster presentations from Teamit’s Head of Partnerships Gianmarco Di Mauro and Study Managers Fabio Riefolo and Elena Palà. Click the links to find out more about Teamit Institute and our publication record.

“ISPE is a chance for experts from across the field of pharmacoepidemiology to come together, share updates and explore innovative solutions. We value our place at the table during these discussions and enjoy the opportunity to reinforce current collaborations as well as forge new connections.”

– Gianmarco Di Mauro, Head of Partnerships at Teamit

Teamit Institute has extensive expertise in pharmacovigilance and has closely been involved in the development and management of pharmacoepidemiology, and real-world evidence studies. For example, Teamit Institute is an active member of VAC4EU (Vaccine monitoring Collaboration for Europe), an international network specialising in the collaborative surveillance of vaccine safety and effectiveness across Europe.

Teamit Institute at ISPE 2024 

As part of VAC4EU, Teamit Institute will present several co-authored posters related to ROC12 and ROC20 and with Pfizer and Johnson & Johnson, as well as two presentations. The information for these posters can be found below:

(093) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in lactating women.

(248) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in pregnant women.

(344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe.

(345) Effectiveness of primary COVID-19 vaccination against severe infection in pediatrics: a cohort study using two linked data sources in Spain.

(359) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment.

These outputs showcase current collaborations in the generation of real-world evidence on vaccine use in Europe and reflect Teamit Institute’s vision of improving quality of life worldwide through collaborative research.

We look forward to seeing you at ISPE 2024 in Berlin, August 24^th-August 28^th, 2024!